Eli Lilly plans to manufacture its new weight-loss pill in the US for patients around the world as Trump presses companies to ...

As CMS maintains limits on GLP-1 coverage for weight loss, new efficacy data and shifting prescribing patterns point to sustained high demand across the drug class. Here are four updates: 1. Federal ...

By making the expected blockbuster pill in the U.S., Lilly may be able to avoid the impact of Trump’s sweeping tariffs, ...

Pharmaceutical companies—including Eli Lilly and Novo Nordisk, which currently dominate the obesity market—have been testing ...

We came across a bearish thesis on DaVita Inc. (NYSE:DVA) on ValueInvestorsClub by Fenkell. In this article, we will ...